Answer
Nov 21, 2024 - 01:35 PM
Neupro, a transdermal patch used to treat Parkinson's disease and restless legs syndrome, was temporarily withdrawn from the U.S. market in 2008 due to crystallization issues with the active ingredient, rotigotine, which affected its delivery through the patch. The manufacturer, UCB, addressed these formulation issues and reintroduced Neupro in the U.S. in 2012 after ensuring the patch's stability and efficacy.
